Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Zirdu who wrote (4905)	7/21/1998 2:00:00 AM
From: scaram(o)uche	Read Replies (1) of 6136

RR: The article indicates that "they found that angiostatin not only killed some of these endothelial cells, but it also sensitized the survivors to radiation." While I believe that the word "killed" is not used appropriately, the indication is that angiostatin induces a differentiation state in endothelial cells which is sensitive to irradiation. There is no reason to believe that 3340 would have a similar action. BTW..... I haven't read the manuscript, but.... the 16-18-64 bit doesn't impress me much. First, it's sort of difficult to talk about "additive" versus "synergistic" with respect to a reduction in tumor volume. Second, if one did add 16 and 18 and subtracted it from 64, you would get a "synergism" that reduced tumor volumes by 30%. That can represent less than two days of growth for an aggressive tumor. Also, think of palpating a subcutaneous tumor on a mouse or rat, and picture the difference in mean tumor diameters that would represent a 30% reduction in volume. A tumor with an average diameter of 6 mm is 26% reduced in volume relative to a tumor of 7 mm. Not much, huh? Rick

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next